Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Madagascar Health Press.
Press releases published on September 9, 2025
Appili Therapeutics to Present Progress on Tularemia Biodefense Vaccine at NATO CBRN Conference
GlobeNewswire
·
September 9, 2025
HALIFAX, Nova Scotia, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that …
Sight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare’s® Expanded Coverage of Glaucoma Surgical Treatments
GlobeNewswire
·
September 9, 2025
MENLO PARK, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to …
Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer
GlobeNewswire
·
September 9, 2025
Late-breaking data from exploratory analyses at WCLC show Libtayo plus chemotherapy demonstrates a more than double five-year overall survival rate of 19.4%, compared to 8.8% with chemotherapy alone In a five-year analysis, consistent efficacy was observed …
Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress
GlobeNewswire
·
September 9, 2025
- Late Breaking Abstract to Present Additional Data from Aclaris’ Phase 2a Trial of ATI-2138 in Atopic Dermatitis- WAYNE, Pa., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused …
Breckenridge Brewery Awarded Silver Certification by the Colorado Green Business Network for Excellence in Sustainability Practices
GlobeNewswire
·
September 9, 2025
LITTLETON, Colo., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Breckenridge Brewery, a craft brewery owned by Tilray Brands, Inc. company (NASDAQ: TLRY and TSX: TLRY), is proud to announce it has received the Silver Certification from the Colorado Green Business …
New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett’s Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions
GlobeNewswire
·
September 9, 2025
FRIENDSWOOD, Texas, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data demonstrating the personalized risk stratification …
With Asthma-Related ER Visits Increasing, AAFA Names 2025 Asthma Capitals
GlobeNewswire
·
September 9, 2025
Washington, DC, Sept. 09, 2025 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) today released its annual Asthma Capitals™ Report, ranking the top 100 most challenging places in the U.S. for living with asthma. This year, Detroit, …
Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum
GlobeNewswire
·
September 9, 2025
WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, …
Harvard Bioscience Announces Appointment of Stephen DeNelsky to Board of Directors
GlobeNewswire
·
September 9, 2025
HOLLISTON, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced the appointment of Stephen DeNelsky to its Board of Directors, effective September 5, 2025. Mr. DeNelsky …
20 Years of the Ubiquitin Revolution: Honoring Nobel Laureate Professor Avram Hershko and the Future of Targeted Protein Degradation
GlobeNewswire
·
September 9, 2025
NEW YORK, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Leaders in the fields of ubiquitin biology and targeted protein degradation (TPD) gathered on September 6, 2025, at the NYU Grossman School of Medicine, to honor SEED Co-Founder and Nobel Laureate Prof. Avram …
Dutch platform makes dermatological care instantly accessible worldwide
GlobeNewswire
·
September 9, 2025
BERGEN OP ZOOM, the Netherlands, Sept. 09, 2025 (GLOBE NEWSWIRE) -- A new Dutch platform has been launched that makes dermatological care accessible internationally. Dermatology2Go (an initiative of Webcamconsult) was developed by two experienced …
Plataforma neerlandesa hace que la atención dermatológica sea instantáneamente accesible en todo el mundo
GlobeNewswire
·
September 9, 2025
BERGEN OP ZOOM, Países Bajos, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Se ha lanzado una nueva plataforma neerlandesa que hace que la atención dermatológica sea accesible a nivel internacional. Dermatology2Go (una iniciativa de Webcamconsult), desarrollada por …
Nederlands platform maakt dermatologische zorg wereldwijd direct toegankelijk
GlobeNewswire
·
September 9, 2025
BERGEN OP ZOOM, Nederland, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Er is een nieuw Nederlands platform gelanceerd dat dermatologische zorg internationaal toegankelijk maakt. Dermatology2Go (een initiatief van Webcamconsult) is ontwikkeld door twee ervaren …
CHAPPER healthcare, AscellaHealth’s Global Pharmaceutical Distributor, Assumes Presidency of EUROPACCESS, Enhancing Access to Innovative Medicines
GlobeNewswire
·
September 9, 2025
WATFORD, United Kingdom and BERWYN, Pa., Sept. 09, 2025 (GLOBE NEWSWIRE) -- CHAPPER healthcare, AscellaHealth’s global pharmaceutical wholesaler, distributor and commercialization service provider, announces its appointment as president of EUROPACCESS, a …
Biosplice Therapeutics Announces First Patient Dosed in NCI-Sponsored Clinical Trial of Cirtuvivint in Acute Myeloid Leukemia and Myelodysplastic Syndromes
GlobeNewswire
·
September 9, 2025
SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering advancements in small molecule inhibition of CDC-like kinases (CLK) and Dual-specificity tyrosine phosphorylation- …
Persephone Biosciences Unveils First-Of-Its-Kind Synbiotic Designed To Restore Critical Gut Microbes In Babies
GlobeNewswire
·
September 9, 2025
Newly released data shows that nine in ten babies lack critical gut microbes needed for healthy development. Persephone’s Daily Synergistic Synbiotic, built on the largest and most comprehensive U.S. infant gut microbiome study, can help restore them. In …
Rarecells Announces New Clinical Data Showing Superior Sensitivity and Tumor Heterogeneity Detection by Synergistic Combination of ctDNA and ISET® CTC-DNA in Patients with Early-Stage Lung Cancer
GlobeNewswire
·
September 9, 2025
NEW YORK and PARIS, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Rarecells, a pioneer in liquid biopsy technologies, today presented new data (poster EP.06.64) at the IASLC 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain, from its BioMolCTC Trial …
Scenic Biotech Appoints Dr. Roland W. Bürli as CSO to Advance Pipeline of Modifier Therapies in Neuro- and Metabolic Diseases
GlobeNewswire
·
September 9, 2025
Scenic Biotech taps Dr. Bürli as Chief Scientific Officer to lead development of innovative drug candidate pipeline fueled by the company’s Cell-Seq platform. Amsterdam, the Netherlands, September 09, 2025 – Scenic Biotech, a pioneer in the field of …
Reaktor and ZAP Surgical win renowned Red Dot Award for ZAP-AXON, a next-generation treatment planning system for brain radiosurgery
GlobeNewswire
·
September 9, 2025
Helsinki, Finland, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Reaktor and ZAP Surgical’s joint redesign of the next-generation ZAP-AXON® Radiosurgery Planning System (RPS) has won the prestigious Red Dot Award in the Brands …
Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG
GlobeNewswire
·
September 9, 2025
– Novartis to acquire Tourmaline Bio for $48.00 per share in cash for a total equity value of approximately $1.4 billion – – Transaction reflects the potential of Tourmaline’s pacibekitug, a long-acting, fully-human, anti-IL-6 monoclonal antibody with best …